Codexis named finalist for CPhI Pharma Awards 2014 for Innovation in Partnering

Codexis has been selected as a finalist for developing a new partnering model for its proprietary CodeEvolver protein engineering technology platform

Codexis, a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, has been named as a finalist for the CPhI Pharma Awards 2014 in the 'Innovation in Partnering' category. The award ceremony will take place on 7 October 2014 in Paris Nord Villepinte, France, as part of the annual CPhI Worldwide exhibition, which is expected to attract around 38,000 visitors from the pharmaceutical industry. Members of the public can vote online for the winner of the 'Partnering' category.

Codexis has been selected as a finalist for developing a new partnering model for its proprietary CodeEvolver protein engineering technology platform. In this new technology licensing model, Codexis allows its customers to use CodeEvolver for custom in-house development of novel biocatalysts. CodeEvolver enables the rapid development of custom-designed biocatalysts that are highly optimised for efficient chemical transformations and manufacturing processes, including those in the field of human healthcare.

In July 2014, Codexis announced a CodeEvolver licensing and collaboration agreement with GSK that marked the first time that Codexis has licensed its protein engineering platform technology to any party in the healthcare field.

'We are very pleased to be named a finalist for the CPhI 2014 Pharma Awards,' said Greg Hughes, Vice President of Business Development at Codexis.

'Our new licensing model can truly accelerate a pharmaceutical company’s ability to apply biocatalysis in order to reduce the cost and increase the efficiency of pharmaceutical manufacturing. It promises to transform the way that one of the world’s largest pharmaceutical companies manufactures its products. We believe that many major drug companies with wide pipelines of small molecule drugs could benefit from this type of transaction.'

The advantages of CodeEvolver stem from the technology’s unique ability to design performing proteins more effectively than other engineering tools on the market, both in terms of its speed and the specificity of the results it delivers. The use of biocatalysts to manufacture pharmaceuticals has the potential to reduce the number of manufacturing steps, reduce the use of hazardous chemicals and the production of toxic waste, and reduce the energy intensity of the process.

Codexis will be exhibiting in Hall 5, Stand 5Q85 at the CPhI Worldwide exhibition.

 

Companies